NewAmsterdam Pharma (NASDAQ:NAMS) versus Akero Therapeutics (NASDAQ:AKRO) Head-To-Head Analysis

NewAmsterdam Pharma (NASDAQ:NAMS) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Institutional & Insider Ownership

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

NewAmsterdam Pharma has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.

Earnings & Valuation

This table compares NewAmsterdam Pharma and Akero Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$14.09 million	154.75	-$176.94 million	N/A	N/A
Akero Therapeutics	N/A	N/A	-$151.76 million	($3.75)	-6.98

Akero Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma.

Profitability

This table compares NewAmsterdam Pharma and Akero Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Akero Therapeutics	N/A	-32.46%	-29.83%

Analyst Ratings

This is a breakdown of current recommendations and price targets for NewAmsterdam Pharma and Akero Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	6	0	3.00
Akero Therapeutics	0	1	7	0	2.88

NewAmsterdam Pharma currently has a consensus target price of $41.60, indicating a potential upside of 76.27%. Akero Therapeutics has a consensus target price of $46.83, indicating a potential upside of 78.89%. Given Akero Therapeutics’ higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than NewAmsterdam Pharma.

Summary

NewAmsterdam Pharma beats Akero Therapeutics on 7 of the 10 factors compared between the two stocks.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About Akero Therapeutics

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.